Strs Ohio bought a new position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 27,141 shares of the company's stock, valued at approximately $1,859,000.
A number of other large investors have also recently made changes to their positions in HSIC. Investment Management Corp VA ADV purchased a new stake in shares of Henry Schein in the 4th quarter worth $32,000. Rakuten Securities Inc. acquired a new position in Henry Schein during the 1st quarter worth approximately $34,000. Whittier Trust Co. increased its position in Henry Schein by 714.3% during the first quarter. Whittier Trust Co. now owns 798 shares of the company's stock worth $55,000 after buying an additional 700 shares in the last quarter. Quarry LP acquired a new position in Henry Schein in the first quarter valued at $71,000. Finally, UMB Bank n.a. increased its position in shares of Henry Schein by 23.2% during the first quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after acquiring an additional 201 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.
Henry Schein Stock Performance
Shares of NASDAQ HSIC traded down $0.69 during mid-day trading on Friday, hitting $67.86. The stock had a trading volume of 5,625,720 shares, compared to its average volume of 1,392,004. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The firm has a market cap of $8.23 billion, a PE ratio of 21.89, a PEG ratio of 2.26 and a beta of 0.86. The company has a 50 day moving average of $68.75 and a two-hundred day moving average of $69.37.
Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same period in the prior year, the business earned $1.23 EPS. The business's quarterly revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on HSIC shares. Baird R W cut shares of Henry Schein from a "strong-buy" rating to a "hold" rating in a report on Monday, July 14th. Robert W. Baird reaffirmed a "neutral" rating and set a $72.00 target price (down previously from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Evercore ISI upgraded shares of Henry Schein from an "in-line" rating to an "outperform" rating and set a $83.00 target price for the company in a research report on Tuesday, August 26th. JPMorgan Chase & Co. reduced their price target on shares of Henry Schein from $80.00 to $76.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Finally, Barrington Research cut their price target on shares of Henry Schein from $86.00 to $78.00 and set an "outperform" rating for the company in a report on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Henry Schein currently has a consensus rating of "Hold" and a consensus price target of $76.67.
Check Out Our Latest Stock Analysis on HSIC
About Henry Schein
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.